Tazobactam
Systematic (IUPAC) name
(2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic
acid 4,4-dioxide
Identifiers
CAS number 89786-04-9
ATC code J01CG02
PubChem ?
DrugBank EXPT03012
Chemical data
Formula C10H12N4O5S
Mol. mass 300.289 g/mol
Molecular Formula C10H11N4NaO5S
Molecular Weight 322.27
Indications and Usage
Treatment of moderate to severe infections caused by -resistant /tazobactam-susceptible,
β-lactamase producing strains of microorganisms in the following
conditions: appendicitis ( complicated by rupture or abscess);
uncomplicated and complicated skin and skin structure infections;
postpartum endometritis or pelvic inflammatory disease;
community-acquired pneumonia (moderate severity only); nosocomial
pneumonia (moderate to severe).
Dosage and Administration
Administer by IV infusion over 30 min.
Nosocomial Pneumonia
Adults
IV Start with 4.5 g every 6 h plus an aminoglycoside (administered
separately) for 7 to 14 days.
Healthy Renal Function (CrCl 90 mL/min or more)
Adults
IV 3.375 g every 6 h totaling 13.5 g ( 12 g/tazobactam 1.5 g) for 7 to
10 days.
Children 2 mo of age and older
IV 80 mg/tazobactam 10 mg per kg every 8 h. Children weighing more than
40 kg with healthy renal function should receive the adult dose.
Children with appendicitis and/or peritonitis 2 mo of age and older
IV Children between 2 and 9 mo of age – 80 mg/tazobactam 10 mg per kg
every 8 h. Children 9 mo of age and older weighing up to 40 kg – 100
mg/tazobactam 12.5 mg per kg every 8 h. Children weighing more than 40
kg – Administer the adult dose.
Renal Function Impairment
Adults
IV CrCl greater than 40 mL/min – 3.375 g every 6 h (all indications),
and 4.5 g every 6 h (nosocomial pneumonia). CrCl 20 to 40 mL/min – 2.25
g every 6 h (all indications), and 3.375 g every 6 h (nosocomial
pneumonia). CrCl less than 20 mL/min – 2.25 g every 8 h (all
indications), and 2.25 g every 6 h (nosocomial pneumonia). There are no
dosage recommendations for children with renal function impairment.
Hemodialysis
Adults
IV Max dosage 2.25 g every 8 h for nosocomial pneumonia and every 12 h
for other indications plus one additional dose of 0.75 g following each
dialysis period.
Continuous Ambulatory Peritoneal Dialysis (CAPD)
Adults
IV 2.25 g every 8 h for nosocomial pneumonia and every 12 h for other
indications.
Drug Interactions
Aminoglycosides
May form microbiologically inactive complexes and should not be mixed in
the same container.
Anticoagulants/Heparin
Frequently monitor coagulation parameters.
Methotrexate
May reduce Cl of methotrexate.
Probenecid
Increases and prolongs t ½ of penicillin levels.
Vecuronium
Neuromuscular blockade may be prolonged.
Incompatibility
Ringer's lactate solution.
Patient Information
* Advise patient or caregiver that medication will be prepared by health
care provider and administered in a health care setting.
* Review dosing schedule and prescribed length of therapy with patient.
Advise patient that dose, dosing frequency, and duration of therapy are
dependent on site of infection, severity of infection, and response to
treatment.
* Advise patient or caregiver to immediately inform health care provider
if injection-site pain or redness, skin rash, hives, itching, or
shortness of breath occur during treatment.
* Advise patient or caregiver to report the following signs of
superinfection to health care provider: black “furry” tongue,
foul-smelling stools, vaginal itching or discharge, white patches in
mouth.
* Warn patient or caregiver that diarrhea containing blood or pus may be
a sign of a serious disorder and, if noted after discharge, to seek
medical care and not treat at home.
PDF DOWNLOAD
WORD DOCUMENT
|
|
India
